sellModerate cluster of 410b5-1 plan
Michelle Gilson sold $1.4M of ACLX
CHIEF FINANCIAL OFFICER at Arcellx, Inc.. 18,009 shares at an average of $75.24, traded Jan 7, 2025, filed Jan 10, 2025.
Warning score
47Value
$1.4M
18,009 shares
Holdings after
9,582
-65% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 65% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-001345, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 3, 2025 | MOption exercise Common Stock10b5-1 | +15,339 | $0.00 | $0 | 38,834 | Jan 10, 2025 |
| Jan 7, 2025 | SOpen-market sale Common Stock10b5-1 | -3,128 | $74.43 | $233k | 24,463 | Jan 10, 2025 |
| Jan 7, 2025 | SOpen-market sale Common Stock10b5-1 | -1,546 | $75.23 | $116k | 22,917 | Jan 10, 2025 |
| Jan 7, 2025 | SOpen-market sale Common Stock10b5-1 | -2,251 | $76.64 | $173k | 20,666 | Jan 10, 2025 |
| Jan 7, 2025 | SOpen-market sale Common Stock10b5-1 | -2,327 | $77.06 | $179k | 18,339 | Jan 10, 2025 |
| Jan 7, 2025 | SOpen-market sale Common Stock10b5-1 | -4,760 | $75.53 | $360k | 13,579 | Jan 10, 2025 |
| Jan 8, 2025 | SOpen-market sale Common Stock10b5-1 | -3,997 | $73.69 | $295k | 9,582 | Jan 10, 2025 |
| Jan 3, 2025 | MOption exercise Restricted Stock Unitderivative10b5-1 | -15,339 | $0.00 | $0 | 15,340 | Jan 10, 2025 |
Related signals
Other insiders at Arcellx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $1.7M 21,034 shares | -97% | |
| 0Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $5,852 73 shares | -0% | |
| 30Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $993k 12,396 shares | -36% | |
| 9Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $291k 3,643 shares | -10% | |
| 18Weak | Arcellx, Inc. | Kavita Patel director | $101k 1,500 shares | -100% | |
| 47Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $785k 12,235 shares | -38% | |
| 17Weak | Arcellx, Inc. | Kavita Patel director | $88k 1,500 shares | -100% | |
| 10Weak | Arcellx, Inc. | Kavita Patel director | $96k 1,500 shares | -100% | |
| 9Weak | Arcellx, Inc. | Kavita Patel director | $86k 1,500 shares | -100% | |
| 10Weak | Arcellx, Inc. | Kavita Patel director | $107k 1,500 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.